Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04365257 · ClinicalTrials.gov registry record · Phase 2
Prazosin to Prevent COVID-19 (PREVENT-COVID Trial)
A Phase 2 study, sponsored by Johns Hopkins University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT04365257: Clinical Trial Phase 2 study, sponsored by Johns Hopkins University.
NCT04365257 is a Phase 2 study that was terminated before completion, run by Johns Hopkins University. The registered enrollment target is 5 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04365257, a Phase 2 study, was terminated before completion, sponsored by Johns Hopkins University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy and safety of prazosin to prevent cytokine storm syndrome and severe complications in hospitalized patients with Coronavirus disease 2019 (COVID-19).
Primary Outcome
Number of participants in each arm who expire.
Interventions
- OTHER Standard of care
- DRUG Prazosin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2020-05-13 |
| Est. Completion | 2022-03-31 |
| Phase | Phase 2 |
Why NCT04365257 stopped before completion
NCT04365257 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Standard of care is the first listed.
NCT04365257 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04365257 about?
NCT04365257 is a clinical study titled "Prazosin to Prevent COVID-19 (PREVENT-COVID Trial)". The purpose of this study is to assess the efficacy and safety of prazosin to prevent cytokine storm syndrome and severe complications in hospitalized patients with Coronavirus disease 2019 (COVID-19).
What is the current status of trial NCT04365257?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2020-05-13. Estimated completion is 2022-03-31.
What interventions are being tested in trial NCT04365257?
The interventions under investigation include: Standard of care (OTHER), Prazosin (DRUG).
Who is sponsoring clinical trial NCT04365257?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04365257's enrollment target sits among peer trials
5 2000th of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI